Harpreet Singh, Immatics CEO

Im­mat­ics an­nounces mul­ti­ple pipeline changes with lat­est fi­nan­cial re­sults

The T-cell biotech Im­mat­ics is look­ing to make some changes to its pipeline.

Im­mat­ics re­leased its 2022 fi­nan­cial re­sults on Tues­day and an­nounced that it’s plan­ning to dis­con­tin­ue its pro­gram for IMA201, an ex­per­i­men­tal cell ther­a­py for sol­id tu­mors that ex­press the anti­gens known as MAGE4/8. It plans to shift fo­cus to IMA401, a TCR bis­pe­cif­ic which goes af­ter the same tar­get. IMA401 al­so has bet­ter po­ten­cy and was de­vel­oped more re­cent­ly ac­cord­ing to Im­mat­ics CEO Harpreet Singh, in an in­ter­view with End­points News. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA